Arena Pharmaceuticals Inc (NASDAQ:ARNA) Q3 2019 Earnings Conference Call Transcript
Nov 07, 2019 • 04:30 pm ET
Good day, everyone, and welcome to the Arena Pharmaceuticals' Financial Results and Corporate Update Conference Call. [Operator Instructions] Following the prepared remarks, we will conduct a question-and-answer session. [Operator Instructions]
I will now turn the call over to Kevin Lind, Chief Financial Officer of Arena. Please go ahead.
Kevin R. Lind
Good afternoon, everyone, and thank you for joining us today. We hope you had a chance to review the news release we issued earlier today announcing our third quarter 2019 financial results. Joining me on today's call is Amit Munshi, our President and Chief Executive Officer; and Dr. Preston Klassen, our Head of Research and Development.
Before we begin, I'd like to remind you that we'll make forward-looking statements that involve risks and uncertainties, including statements about our focus, plans, goals, strategy, expectations, R&D programs, regulatory activities, products and operations and those of our collaborators and licensees, and other statements that are not historical facts.
These statements are made in the context of the risks and uncertainties that are discussed in our filings with the US Securities and Exchange Commission, which can be found on the SEC website at www.sec.gov. And include risks related to timing and outcomes of regulatory decisions and discussions; timing of preclinical and clinical trials, including patient recruitment for clinical trials, which is competitive and challenging and may take longer than we project; preclinical and clinical results and the timing of such results, which may not be as expected or sufficient for further development, regulatory approval or commercialization; collaboration and licensing activities; and the amount and allocation of our available financial and other resources. Our actual results may differ materially from our forward-looking statements.
Now I'd like to turn the call over to Amit.
Amit D. Munshi
Thanks, Kevin, and hi, everyone, and thanks for joining our call today. During our comments today we will provide pipeline updates and conclude with a financial review of the third quarter of 2019.
Arena continues to make exceptionally strong progress on offerings, clinical, operational and financial meeting or exceeding our objectives across the Board. Last week we were pleased to have initiated our Phase 2 ADVISE trial in atopic dermatitis. We believe this is an important first step in the bottling of the therapeutic applications for Etrasimod. We continue to expect to initiate our Phase 2b/3 program in Crohn's disease this year and Preston will provide the additional color on our plans later in this call.
Beyond UC, CD and atopic dermatitis, we expect to further expand etrasimod's utility in additional indications going forward. We believe -- we continue to believe that once a day oral agent of etrasimod's profile offers tremendous promise in the treatment of a broad range of immune-mediated inflammatory diseases. We look forward to sharing our plans on two additional immune medications in the next few months.
With regards to APD418, our preclinical assets for decompensated heart failure, we remain on track to file an IND in the fourth quarter of this year.
I'd now like to turn to call over